Accessibility Menu
 
Keros Therapeutics logo

Keros Therapeutics

(NASDAQ) KROS

Current Price$10.52
Market Cap$207.77M
Since IPO (2020)-48%
5 Year-79%
1 Year-25%
1 Month-10%

Keros Therapeutics Financials at a Glance

Market Cap

$207.77M

Revenue (TTM)

$33.18M

Net Income (TTM)

$85.14M

EPS (TTM)

$-3.01

P/E Ratio

-3.49

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$10.52

Volume

20,103

Open

$10.81

Previous Close

$10.52

Daily Range

$10.30 - $10.81

52-Week Range

$10.30 - $22.55

KROS: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Keros Therapeutics

Industry

Biotechnology

Employees

78

CEO

Jasbir S. Seehra, PhD

Headquarters

Lexington, MA 02421, US

KROS Financials

Key Financial Metrics (TTM)

Gross Margin

96%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-17%

Return on Capital

-37%

Return on Assets

-27%

Earnings Yield

-28.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$207.77M

Shares Outstanding

19.79M

Volume

20.10K

Avg. Volume

424.82K

Financials (TTM)

Gross Profit

$242.55M

Operating Income

$70.62M

EBITDA

$72.13M

Operating Cash Flow

$107.50M

Capital Expenditure

$1.55M

Free Cash Flow

$105.95M

Cash & ST Invst.

$287.42M

Total Debt

$16.88M

Keros Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$367.00K

-99.8%

Gross Profit

$36.00K

-100.0%

Gross Margin

-9.81%

N/A

Market Cap

$207.77M

N/A

Market Cap/Employee

$1.27M

N/A

Employees

163

N/A

Net Income

$23.71M

-116.0%

EBITDA

$25.47M

-116.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$265.19M

-62.2%

Accounts Receivable

$2.65M

-86.3%

Inventory

$0.00

N/A

Long Term Debt

$13.81M

-15.3%

Short Term Debt

$2.50M

+19.0%

Return on Assets

-27.26%

N/A

Return on Invested Capital

-36.85%

N/A

Free Cash Flow

$3.60M

-102.2%

Operating Cash Flow

$3.53M

-102.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAGENiagen Bioscience Inc
$3.65-3.95%
RGNXREGENXBIO Inc.
$5.72-8.41%
VSTMVerastem, Inc.
$4.32-8.28%
RIGLRigel Pharmaceuticals, Inc.
$29.01-9.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.95-0.04%
FFord Motor Company
$13.40-0.07%
POETPoet Technologies
$15.97-0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.06-0.10%

Questions About KROS

What is the current price of Keros Therapeutics?

Keros Therapeutics is trading at $10.52 per share.

What is the 52-week range for Keros Therapeutics?

Over the past 52 weeks, Keros Therapeutics has traded between $10.30 and $22.55.

How much debt does Keros Therapeutics have?

As of the most recent reporting period, Keros Therapeutics reported total debt of $16.31M.

How much cash does Keros Therapeutics have on hand?

Keros Therapeutics reported $281.50M in cash and cash equivalents in its most recent financial results.

What is Keros Therapeutics’s dividend yield?

Keros Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.